Lazard Asset Management
CPRX

Lazard Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Lazard Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$544K Sell
17,293
-34,599
-67% -$1.02M ﹤0.01% 1412
2026
Q1 		$1.28M Sell
51,892
-3,187
-6% -$75.9K ﹤0.01% 1084
2025
Q4 		$1.29M Buy
55,079
+5,755
+12% +$128K ﹤0.01% 1072
2025
Q3 		$972K Buy
49,324
+5,355
+12% +$110K ﹤0.01% 1150
2025
Q2 		$953K Sell
43,969
-129,257
-75% -$3.05M ﹤0.01% 1316
2025
Q1 		$4.2M Buy
173,226
+47,883
+38% +$1.08M 0.01% 733
2024
Q4 		$2.61M Buy
125,343
+46,318
+59% +$995K ﹤0.01% 794
2024
Q3 		$1.57M Buy
79,025
+56,144
+245% +$1.04M ﹤0.01% 932
2024
Q2 		$353K Sell
22,881
-7,453
-25% -$116K ﹤0.01% 1343
2024
Q1 		$482K Buy
30,334
+8,133
+37% +$123K ﹤0.01% 1066
2023
Q4 		$373K Buy
22,201
+1,127
+5% +$15.4K ﹤0.01% 1197
2023
Q3 		$246K Buy
21,074
+3,078
+17% +$41.2K ﹤0.01% 1314
2023
Q2 		$241K Sell
17,996
-5,182
-22% -$74.6K ﹤0.01% 1296
2023
Q1 		$384K Sell
23,178
-16,980
-42% -$280K ﹤0.01% 1157
2022
Q4 		$746K Buy
40,158
+17,032
+74% +$262K ﹤0.01% 1047
2022
Q3 		$296K Buy
23,126
+418
+2% +$4.95K ﹤0.01% 1189
2022
Q2 		$159K Sell
22,708
-47,567
-68% -$349K ﹤0.01% 1341
2022
Q1 		$582K Buy
70,275
+62,901
+853% +$445K ﹤0.01% 1081
2021
Q4 		$49K Sell
7,374
-1,441
-16% -$9.48K ﹤0.01% 1747
2021
Q3 		$46K Buy
+8,815
New +$48.2K ﹤0.01% 1717
2021
Q2 		– Sell
-21,583
Closed -$99K – 1977
2021
Q1 		$99K Buy
+21,583
New +$85.7K ﹤0.01% 1206
2020
Q4 		– Sell
-18,161
Closed -$53K – 1858
2020
Q3 		$53K Buy
18,161
+6,791
+60% +$26.6K ﹤0.01% 1170
2020
Q2 		$52K Sell
11,370
-1,360
-11% -$6.11K ﹤0.01% 1217
2020
Q1 		$49K Buy
12,730
+8,960
+238% +$36.8K ﹤0.01% 1172
2019
Q4 		$14K Buy
+3,770
New +$17.6K ﹤0.01% 1322

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Lazard Asset Management's CPRX Position: Q2 2026 in Review

Lazard Asset Management reduced its Catalyst Pharmaceutical (CPRX) stake by 67% in Q2 2026, selling an estimated $1.02M and leaving 17,293 shares worth $544K. The position accounts for ﹤0.01% of the portfolio, ranked #1412.

Lazard Asset Management first reported a position in CPRX in Q4 2019 and has held it in 25 quarters since. The position peaked at $4.2M in Q1 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Lazard Asset Management held 17,293 shares of Catalyst Pharmaceutical worth $544K as of Q2 2026.
  • Lazard Asset Management sold 34,599 Catalyst Pharmaceutical shares in Q2 2026, an estimated $1.02M.
  • Catalyst Pharmaceutical made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #1412 holding.
  • Lazard Asset Management first reported a position in Catalyst Pharmaceutical in Q4 2019 and has held it in 25 quarters since.
  • Lazard Asset Management's Catalyst Pharmaceutical position peaked at $4.2M in Q1 2025.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.